KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Non-Current Deffered Revenue (2016 - 2025)

Historic Non-Current Deffered Revenue for Ionis Pharmaceuticals (IONS) over the last 17 years, with Q3 2025 value amounting to $107.9 million.

  • Ionis Pharmaceuticals' Non-Current Deffered Revenue fell 3790.51% to $107.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $107.9 million, marking a year-over-year decrease of 3790.51%. This contributed to the annual value of $156.5 million for FY2024, which is 3511.01% down from last year.
  • According to the latest figures from Q3 2025, Ionis Pharmaceuticals' Non-Current Deffered Revenue is $107.9 million, which was down 3790.51% from $125.1 million recorded in Q2 2025.
  • Ionis Pharmaceuticals' 5-year Non-Current Deffered Revenue high stood at $402.0 million for Q1 2021, and its period low was $107.9 million during Q3 2025.
  • Over the past 5 years, Ionis Pharmaceuticals' median Non-Current Deffered Revenue value was $254.4 million (recorded in 2023), while the average stood at $255.4 million.
  • Per our database at Business Quant, Ionis Pharmaceuticals' Non-Current Deffered Revenue crashed by 1408.08% in 2021 and then plummeted by 3790.51% in 2025.
  • Quarter analysis of 5 years shows Ionis Pharmaceuticals' Non-Current Deffered Revenue stood at $351.9 million in 2021, then decreased by 18.22% to $287.8 million in 2022, then fell by 16.19% to $241.2 million in 2023, then crashed by 35.11% to $156.5 million in 2024, then crashed by 31.05% to $107.9 million in 2025.
  • Its last three reported values are $107.9 million in Q3 2025, $125.1 million for Q2 2025, and $140.7 million during Q1 2025.